UNSPSC 51292024: Fluvoxamine maleate

This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5LGN83G74V. European Medicines Agency schedules Fluvoxamine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13908MIG. Fluvoxamine maleate generally arises in the molecular formula C15H21F3N2O2.C4H4O4. The term 'fluvoxamine maleate' is a United States Adopted Name designation.

Most nations, for tariff and trade purposes, schedule fluvoxamine maleate under HS 29280090 and SITC 51486. As of Q4 2014, FLUVOXAMINE MALEATE remains US FDA's Preferred Term for this commodity. Fluvoxamine maleate bears US NLM identifiers UMLS ID C0086307 and NCI Concept Code C29063. SMILES: COCCCC/C(=N\OCCN)/C1CCC(CC1)C(F)(F)F.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51292024 Fluvoxamine maleate is a Commodity code that nominally names a specific antidepressant pharmaceutical; however, the recent state and local opportunities posted under this code reflect broader pharmaceutical procurement — generic multi-source drugs, over-the-counter products, naloxone, and direct-to-manufacturer prescription programs — rather than fluvoxamine specifically. State and local governments use this code tier to solicit pharmaceutical supply contracts through multiple channels: direct purchases from county health departments, cooperative purchasing alliances spanning multiple states, and exploratory requests for information from state health and human services agencies. The mix of issuing bodies includes county health systems (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance administering across Minnesota and Oregon).

Recent activity shows geographic spread across Florida, Texas, Minnesota, and Oregon. Representative opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through an IFB; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) gathering market intelligence on direct-to-manufacturer prescription programs without a formal evaluation phase; and MMCAP's S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products with pricing weighted 75 percent on competitiveness and contracts effective July 1, 2026. The Seminole County procurement requires quarterly deliveries to a community health building with vendor responsibility for shipping; the MMCAP solicitation mandates relationships with specific authorized wholesalers and compliance with cGMP and Drug Supply Chain Security Act standards, with a 3 percent administrative fee and performance penalties ranging from $200 to $1,500 per violation.